Predicted to have long-chain fatty acid transporter activity; long-chain fatty acid-CoA ligase activity; and very long-chain fatty acid-CoA ligase activity. Involved in response to nutrient. Predicted to localize to several cellular components, including brush border membrane; endoplasmic reticulum membrane; and microvillus. Biomarker of fatty liver disease. Orthologous to human SLC27A4 (solute carrier family 27 member 4); PARTICIPATES IN eicosanoid signaling pathway via peroxisome proliferator-activated receptor gamma; INTERACTS WITH 2,4-dinitrotoluene; 4-amino-2,6-dinitrotoluene; bisphenol A.
Fatp4; fatty acid transport protein 4; LOC311839; long-chain fatty acid transport protein 4; solute carrier family 27 (fatty acid transporter), member 4
[Dietary Sucrose co-treated with Dietary Fats co-treated with bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Tetrachlorodibenzodioxin co-treated with 2 more ...
[Dietary Sucrose co-treated with Dietary Fats co-treated with bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Tetrachlorodibenzodioxin co-treated with 2 more ...
[Dietary Sucrose co-treated with Dietary Fats co-treated with bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Tetrachlorodibenzodioxin co-treated with 2 more ...
[Dietary Sucrose co-treated with Dietary Fats co-treated with bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Tetrachlorodibenzodioxin co-treated with 2 more ...
[Clofibrate co-treated with Acetaminophen] affects the expression of SLC27A4 mRNA, PPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of SLC27A4 mRNA]
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC27A4 mRNA
PPARA gene mutant form inhibits the reaction [Fenofibrate results in increased expression of SLC27A4 mRNA], PPARA gene mutant form inhibits the reaction [Fenofibrate results in increased expression of SLC27A4 protein]
PPARA gene mutant form inhibits the reaction [linalool results in increased expression of SLC27A4 mRNA], PPARA gene mutant form inhibits the reaction [linalool results in increased expression of SLC27A4 protein]
[Clofibrate co-treated with Acetaminophen] affects the expression of SLC27A4 mRNA, PPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of SLC27A4 mRNA]
Dietary Fats, Unsaturated promotes the reaction [perfluorooctanoic acid results in increased expression of SLC27A4 mRNA], PPARA protein promotes the reaction [perfluorooctanoic acid results in increased expression of SLC27A4 mRNA]
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC27A4 mRNA
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC27A4 mRNA
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Gene-Chemical Interaction Annotations
